Data as of Nov 26
| +0.05 / +1.61%|
The 3 analysts offering 12-month price forecasts for Corcept Therapeutics Inc have a median target of 2.50, with a high estimate of 3.00 and a low estimate of 1.50. The median estimate represents a -20.63% decrease from the last price of 3.15.
The current consensus among 3 polled investment analysts is to Hold stock in Corcept Therapeutics Inc. This rating has held steady since November, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.